FDA SETS ASIDE JULY 28 FOR ADDITIONAL ZOVIRAX Rx-TO-OTC SWITCH REVIEW
This article was originally published in The Tan Sheet
Executive Summary
FDA SETS ASIDE JULY 28 FOR ADDITIONAL ZOVIRAX Rx-TO-OTC SWITCH REVIEW by its Nonprescription Drugs Advisory Committee and Antiviral Drugs Advisory Committee, according to an FDA list of tentative meeting dates. FDA has set a public hearing for May 19 from 8 a.m. to 3:30 p.m. to solicit opinions from scientists, professional groups and consumers on issues related to the over- the-counter availability of Burroughs Wellcome's Zovirax (acyclovir) for the treatment of recurrent genital herpes ("The Tan Sheet" March 14, p. 1). Following the hearing, the two advisory committees will meet from 3:30 p.m. to 6 p.m.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning